医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

RBCC and n3D Take World’s First Commercially Available 3D Bioprinting System Global

2014年05月22日 PM06:00
このエントリーをはてなブックマークに追加


 

MIRAMAR BEACH, Fla.

As they continue to spread the word about the revolutionary BiO Assay, joint venture partners Rainbow Coral Corp. (OTCBB: RBCC) and Nano3D Biosciences (n3D) are taking the 3D bioprinting technology international this spring and summer.

Beginning this month, cutting-edge research utilizing the BiO Assay will be presented at a number of high-profile healthcare and biomedical conferences in North America, Europe, Asia and South America. Glauco R. Souza, the president and chief science officer of n3D, has already delivered successful presentations at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Conference in Toronto, where the company collaborated with pharmaceuticals giant AstraZeneca, as well as at Tissue Models & Drug Screening Technologies Conference in Berlin.

In the coming weeks, n3D will present at the International 3D Bioprinting Congress in Singapore and the National Symposium of Nanotechnology and Nanomedicine in Brazil, exhibiting the BiO Assay’s full potential to international crowds of doctors and researchers hungry for powerful new tools in the fight against illness and disease.

The BiO Assay is the world’s first commercially available 3D bioprinting system designed for high throughput and high-content drug screening. The automated toxicity assay uses biocompatible magnetic nanoparticles to print cells into 3D structures much faster and more affordably than competing bioprinting tech currently on the market.

The BiO Assay represents a revolution in pharmaceutical research, offering better and faster results than have previously been possible.

RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and develop new medical and research technology innovations to compete alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). In 2012, Rainbow Biosciences acquired an equity interest in n3D.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

CONTACT

Rainbow Coral Corp.
Kimberly Palmer, 850-269-7230
President
and CEO
info@rainbowcoral.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent